All we can do now is wait and see, the DX merger i

Quote:

---

All we can do now is wait and see, the DX merger is a terrible deal from what we have seen and in my opinion, only seems to prove that Lympro is a failure.

---

You know, i've asked myself that question too.... why was no one else interested in our assets?

Lympro i truely don't know what to expect from that asset but MsPrecise looks like a great asset seeing how that is superior to the standard that is on the market right now.

Why would big pharma not scoop up this great asset?
You would think big pharma's would be lining up to get their hands on such an asset.

The Avant merger was like a quick (1.5 month) decision instead of just a spin-off that Gerald was planning. Was that the best we could get? I thought we had plenty of options to choose from and thats why it was taking so long? I was expecting a company that already had revenue's and would be listed on the NASDAQ or some better exchange then the OTC company we got now, that still needs funding of its own.

Is big pharma not interested because MsPrecise stil costs 10million (give or take a million) to develope further and still needs validation studies for the CLIA commercialization?

Same goes for Avant's asset OvaDx. Why doesn't Roche who owns an inferior diagnotisic tool for ovarian cancer just buy out OvaDx to replace their CA 125 test?

Gregg Linn said he needed what? 3 million (or was it 5?) to take OvaDx through
the necesarry steps to bring it to market if i understanded it correctly?

A few million for a superior test like OvaDx would be a great investment for Roche and i assume Roche does not want this test landing in competition's hands. We are talking about a 2 billion market potential!
If i were Roche i would buy out Avant real fast before someone else runs away with OvaDx!

Found an interesting link that makes Roche's diagnostic test not sound al that great and more the reason to buy OvaDx:

http://www.mayoclinic.org/diseases-conditions...q-20058528

To quickly sum up my ramblings....

I don't understand why big pharma would not just scoop up OvaDx or MsPrecise since they are so superior to whats on the market currently????

Could it have to do with the fact that further validation still needs to be done and its not a sure thing these diagnostic tools ever get to market?

Chip in with any logical explanation folks.